Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

NCT04440436 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

NHL

Interventions

DRUG: IM19 CAR-T Cells

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.

Collaborators

[object Object]